Avalo-Final_Black-01.jpg
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo-Final_Black-01.jpg
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023 07:00 ET | Avalo Therapeutics
Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration...
Avalo-Final_Black-01.jpg
Avalo to Participate in SVB Securities Therapeutics Forum
July 06, 2023 16:01 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo-Final_Black-01.jpg
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
June 26, 2023 07:00 ET | Avalo Therapeutics
AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated...
Avalo-Final_Black-01.jpg
Avalo to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo-Final_Black-01.jpg
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 22, 2023 07:00 ET | Avalo Therapeutics
Avalo’s SAB is comprised of key opinion leaders in immunology and the LIGHT-signaling network WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq:...
Avalo-Final_Black-01.jpg
Avalo to Present at ATS 2023 Respiratory Innovation Summit
May 15, 2023 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo-Final_Black-01.jpg
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo-Final_Black-01.jpg
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023 16:01 ET | Avalo Therapeutics
Topline data expected in the second quarter of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Disclosed cash of approximately $16.7 million as of March 31, 2023 ...
Avalo-Final_Black-01.jpg
Avalo Reports 2022 Financial Results and Provides Business Updates
March 29, 2023 07:30 ET | Avalo Therapeutics
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023Disclosed cash of approximately $13 million as of...